Mizuho Markets Americas LLC Buys 63,200 Shares of Cencora, Inc. $COR

Mizuho Markets Americas LLC increased its stake in shares of Cencora, Inc. (NYSE:COR) by 28.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 287,900 shares of the company’s stock after purchasing an additional 63,200 shares during the quarter. Cencora makes up approximately 2.5% of Mizuho Markets Americas LLC’s holdings, making the stock its 9th largest holding. Mizuho Markets Americas LLC’s holdings in Cencora were worth $90,441,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Cencora by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after buying an additional 221,570 shares during the last quarter. State Street Corp boosted its position in Cencora by 1.3% during the fourth quarter. State Street Corp now owns 9,305,507 shares of the company’s stock worth $3,142,935,000 after acquiring an additional 115,191 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after acquiring an additional 4,123,795 shares during the last quarter. Geode Capital Management LLC grew its stake in Cencora by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock worth $1,843,268,000 after acquiring an additional 169,055 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Cencora by 6.5% in the 4th quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock valued at $1,682,859,000 after acquiring an additional 304,760 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on COR. William Blair began coverage on Cencora in a research note on Tuesday, April 28th. They set a “market perform” rating on the stock. Weiss Ratings downgraded Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. Morgan Stanley set a $342.00 target price on Cencora in a research note on Friday, May 8th. Barclays reduced their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 10th. Finally, Evercore set a $360.00 price target on Cencora in a research note on Wednesday, April 8th. Eleven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $367.75.

Insider Buying and Selling

In other news, Director Lauren M. Tyler purchased 550 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the purchase, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.38% of the stock is owned by corporate insiders.

Cencora Stock Up 1.3%

Shares of COR opened at $304.57 on Friday. The firm has a market cap of $59.26 billion, a PE ratio of 23.36, a price-to-earnings-growth ratio of 1.67 and a beta of 0.58. The company’s fifty day moving average is $283.47 and its two-hundred day moving average is $316.51. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is 18.40%.

Cencora announced that its board has initiated a share buyback program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.